ストックスクリーナーアプリを入手
5.81
2.68%
-0.16
前日終値:
$5.97
開ける：
$5.95
24時間の取引高:
15.08M
Relative Volume:
0.69
時価総額：
$2.73B
収益：
$64.60M
当期純損益:
$-377.75M
株価収益率:
-3.7484
EPS:
-1.55
ネットキャッシュフロー:
$-335.64M
1週間 パフォーマンス:
-13.02%
1か月 パフォーマンス:
-24.25%
6か月 パフォーマンス:
-16.76%
1年 パフォーマンス:
-41.73%
1日の値動き範囲:
$5.77
$6.005
1週間の範囲:
$5.77
$6.94
52週間の値動き範囲:
$5.60
$12.36
Recursion Pharmaceuticals Inc Stock (RXRX) Company Profile
名前
Recursion Pharmaceuticals Inc
セクター
電話
(385) 269-0203
住所
41S RIO GRANDE STREET, SALT LAKE CITY
RXRX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RXRX
Recursion Pharmaceuticals Inc
|
5.81 | 2.73B | 64.60M | -377.75M | -335.64M | -1.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
492.69 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
637.36 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
589.15 | 35.93B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
268.46 | 34.75B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
267.39 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Recursion Pharmaceuticals Inc Stock (RXRX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2023-05-22 | 開始されました | Morgan Stanley | Equal-Weight |
| 2023-03-16 | 開始されました | Needham | Buy |
| 2022-09-16 | 開始されました | KeyBanc Capital Markets | Overweight |
| 2022-04-18 | ダウングレード | BofA Securities | Buy → Neutral |
| 2022-03-04 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2021-09-21 | 開始されました | Berenberg | Buy |
| 2021-05-11 | 開始されました | BofA Securities | Buy |
| 2021-05-11 | 開始されました | Goldman | Neutral |
| 2021-05-11 | 開始されました | JP Morgan | Neutral |
| 2021-05-11 | 開始されました | KeyBanc Capital Markets | Overweight |
| 2021-05-11 | 開始されました | SVB Leerink | Outperform |
すべてを表示
Recursion Pharmaceuticals Inc (RXRX) 最新ニュース
Recursion Pharmaceuticals CEO sells $836,986 in stock - Investing.com India
Why Recursion Pharmaceuticals Inc. (RXRX) Performed Worst On Tuesday? - MSN
Recursion: A Look At Near-Term Phase 1b And Phase 2 Catalysts (NASDAQ:RXRX) - Seeking Alpha
(RXRX) Investment Report - Stock Traders Daily
Is Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) the Best AI Stock to Invest in According to Reddit? - Insider Monkey
12 Best AI Stocks to Invest in According to Reddit - Insider Monkey
Why Recursion Pharmaceuticals (RXRX) Went Up on Monday? - MSN
Why Recursion Pharmaceuticals (RXRX) Dipped More Than Broader Market Today - Yahoo Finance
RXRX Quantitative Stock AnalysisBenjamin Graham - Nasdaq
Recursion Pharmaceuticals (NasdaqGS:RXRX) Jumps 12% Following US$500M Equity Offering - Yahoo Finance
Recursion Pharma Down 37% in a Month: Buy, Sell or Hold the Stock? - Zacks Investment Research
Recursion Pharmaceuticals Strengthens Board with New Appointments - TipRanks
Recursion Bolsters Board of Directors with Former FDA Principal Deputy Commissioner Dr. Namandjé Bumpus and Mammoth Biosciences COO and CFO Elaine Sun - Yahoo Finance
These 10 biotech companies are changing how we discover new drugs and treat complex diseases - Fast Company
Recursion Pharmaceuticals's Options: A Look at What the Big Money is Thinking - Benzinga
Jones Financial Companies Lllp Has $229,000 Position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) - Defense World
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought - AOL
HAYA Therapeutics Appoints Former Exscientia Executive Dr. Richard Law as Chief Business Officer - Business Wire
Proficio Capital Partners LLC Makes New $163,000 Investment in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) - Defense World
Recursion Pharmaceuticals: Stretched Thin And Chasing Unicorns - Seeking Alpha
Jim Cramer on Recursion Pharmaceuticals, Inc. (RXRX): ‘We’re Going To Have To Hold Off’ - Insider Monkey
Recursion Pharma Gets A Price-Target Cut After Q4 Miss: Retail Bearish Even As Cathie Wood's Ark Buys The Dip - MSN
Why Recursion Pharmaceuticals Stock Is Sinking Today - Yahoo Finance
Jim Cramer’s Latest Lightning Round: 8 Stocks in Focus - Insider Monkey
Is This Beaten-Down Artificial Intelligence (AI) Stock a Buy? - Nasdaq
Cathie Wood-Led Ark Invest Roblox, Roku, UiPath As Markets Take A Dip - Benzinga
QRG Capital Management Inc. Grows Holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) - Defense World
This Is What Whales Are Betting On Recursion Pharmaceuticals - Benzinga
Private Advisor Group LLC Increases Stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) - Defense World
4 Things You Need to Know if You Buy Recursion Pharmaceuticals Stock Today - MSN
This Biotech Stock Could Be the Best Investment of the Decade - The Globe and Mail
April 25th Options Now Available For Recursion Pharmaceuticals (RXRX) - Nasdaq
Down Over 40%, Is Recursion Pharmaceuticals a Buy on the Dip? - MSN
IFP Advisors Inc Acquires 7,455 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) - Defense World
Recursion Pharmaceuticals (RXRX) Remains Optimistic Despite Q4 Disappointment - TipRanks
TechBio Latest News - substack.com
How To Trade (RXRX) - Stock Traders Daily
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Q4 2024 Earnings Call Transcript - MSN
News Flash: Analysts Just Made A Sizeable Upgrade To Their Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Forecasts - Yahoo Finance
Recursion Pharmaceuticals Shares Dip Amid Revenue Timing - TipRanks
Why Recursion Pharmaceuticals, Inc. (RXRX) Crashed on Monday - MSN
Rhumbline Advisers Has $2.26 Million Stock Holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) - Defense World
Recursion Pharmaceuticals Inc (RXRX) 財務データ
収益
当期純利益
現金流量
EPS
0.39%
0.34%
大文字化:
|
ボリューム (24 時間):